Sangamo Therapeutics, Inc

Ownership Transactions Reported by 21 Insiders

Symbol
SGMO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
501 Canal Blvd., Richmond, CA

There are no Buy or Sell transactions made by insiders since 11/21/2023

Sangamo Therapeutics, Inc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Biogen Inc. 10%+ Owner $6.75M Sep 26, 2023
Sandy Macrae PRESIDENT, CEO AND DIRECTOR, Director $2.17M Aug 24, 2024
Nathalie Dubois-Stringfellow Svp Chief Development Officer $726K Aug 24, 2024
Scott B. Willoughby Svp, Gen. Counsel & Secretary $714K Aug 24, 2024
Prathyusha Duraibabu Svp, Chief Financial Officer $712K Aug 24, 2024
Gregory D. Davis Head of Research & Technology $175K Oct 18, 2024
Amy Pooler Vp, Head Of Research $167K Aug 24, 2024
David Mark McClung EVP, Chief Operating Officer $81.2K Nov 25, 2023
Rolf Andrew Ramelmeier EVP, Technical Operations $65.5K May 25, 2023
Parker H Stewart Director $52.6K Jun 4, 2024
Jason D. Fontenot SVP, Chief Scientific Officer $52.1K Nov 25, 2023
Karen L. Smith Director $46.3K Jun 4, 2024
James R. Meyers Director $44.8K Jun 4, 2024
Robert Carey Director $44.8K Jun 4, 2024
Kenneth J. Hillan Director $44.8K Jun 4, 2024
John Markels Director $42.8K Jun 4, 2024
Margaret Horn Director $34.6K Jun 4, 2024
Courtney Beers Director $34.6K Jun 4, 2024
Robert J. Schott SVP, Head of Development $28.9K Feb 25, 2022
Joseph S. Zakrzewski Director $23.2K Feb 25, 2022
Saira Ramasastry Director $13.6K Feb 25, 2022

Recent Insider Transactions by Companies or Individuals for Sangamo Therapeutics, Inc

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.